USPTO serial 86605519
H
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 28, 2017
- Examiner
- SETTLES LEWIS, SHAILA E
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with H?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Hisun Pfizer Pharmaceuticals Co., Ltd.
Zhejiang Province, CN
Other trademarks owned by Hisun Pfizer Pharmaceuticals Co., Ltd.
Hisun Pfizer Pharmaceuticals Co., Ltd.
Zhejiang Province, CN
Other trademarks owned by Hisun Pfizer Pharmaceuticals Co., Ltd.
Hisun Pfizer Pharmaceuticals Co., Ltd.
Zhejiang Province, CN
Other trademarks owned by Hisun Pfizer Pharmaceuticals Co., Ltd.
HANHUI PHARMACEUTICALS CO., LTD.
HANGZHOU CITY, ZHEJIANG PROVINCE, CN
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Catherine M.C. Farrelly
CATHERINE M.C. FARRELLY Frankfurt Kurnit Klein & Selz PC28 Liberty StreetNew York, NY 10005UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Vitamin preparations; medicines for human purposes for the treatment of Cancers, the prevention of organ rejection by renal transplant patients, hypertension, hyperlipidemia, hypercholesterolemia, heart disease, prevention of chest pain, congestive heart failure, diabetes, Rheumatic Disorders, Collagen Diseases, Dermatologic Diseases, Allergies, Ophthalmic Diseases, Respiratory Diseases, Hematologic Disorders, Neoplastic Diseases, Edematous States, gastric ulcer, duodenal ulcer, reflux esophagitis, Zollinger-Ellison syndrome, depression, obsessive-compulsive disorder, schizophrenia, epilepsy, seizures, spasms, Endocrine Disorders, and adrenocortical insufficiency; capsules for pharmaceutical purposes for the treatment of hypertension, hyperlipidemia, schizophrenia, Urethritis, non-gonococcal urethritis, prostatitis, gonorrhea, cystitis, epididymitis, intrauterine infection, pyelonephritis, endonephritis, pyelocystiti; pharmaceutical preparations for the treatment of Cancers, the prevention of organ rejection by renal transplant patients, hypertension, hyperlipidemia, hypercholesterolemia, heart disease, prevention of chest pain, chronic congestive heart failure, diabetes, Rheumatic Disorders, Collagen Diseases, Dermatologic Diseases, Allergic States, Ophthalmic Diseases, Respiratory Diseases, Hematologic Disorders, Neoplastic Diseases, Edematous States, gastric ulcer, duodenal ulcer, reflux esophagitis, Zollinger-Ellison syndrome, depression, obsessive-compulsive disorder, schizophrenia, epilepsy, seizures, spasms, Endocrine Disorders, adrenocortical insufficiency, respiratory tract infections, Urinary tract infections, Intra-abdominal infections, Skin and skin structure infections, septicemia, Gynecological infections, Febrile neutropenic infections, Bone and joint infections, Polymicrobic infections, Urethritis, non-gonococcal urethritis, prostatitis, gonorrhea, cystitis, epididymitis, intrauterine infection, pyelonephritis, endonephritis, pyelocystitis, Superficial pyogenic infection, Deep suppurative disease, bronchitis, asthmatoid bronchitis, bronchiectasis, alveobronchiolitis, bacterial pneumonia, allotype pneumonia, Suppurative lung disease, Syphilis, Otitis media, nasosinusitis, hypognathadenitis, Dysentery, enteritis, transmissible alimentary toxicosis, angiocholitis, cholecystitis, Peritonitis and Septicemia, community-acquired pneumonia, urogenital tract infection, endocarditis, bacterial infection, meningitis, and granulocytopenia; chemico-pharmaceutical preparations for the treatment of cancers, the prevention of organ rejection by renal transplant patients, hypertension, hyperlipidemia, hypercholesterolemia, heart disease, prevention of chest pain, chronic congestive heart failure, diabetes, Rheumatic Disorders, Collagen Diseases, Dermatologic Diseases, Allergic States, Ophthalmic Diseases, Hematologic Disorders, humanases , Neoplastic Diseases, Edematous States, gastric ulcer, duodenal ulcer, reflux esophagitis and Zollinger-Ellison syndrome, depression, obsessive-compulsive disorder, schizophrenia, epilepsy, seizures, spasms, Endocrine Disorders, adrenocortical insufficiency, Lower respiratory tract infections, Urinary tract infections, Intra-abdominal infections, Skin and skin structure infections, septicemia, Gynecological infections, Febrile neutropenic infections, Bone and joint infections, Polymicrobic infections, Urethritis, non-gonococcal urethritis, prostatitis, gonorrhea, cystitis, epididymitis, intrauterine infection, pyelonephritis, endonephritis, pyelocystitis, Superficial pyogenic infection, Deep suppurative disease, bronchitis, asthmatoid bronchitis, bronchiectasis, alveobronchiolitis, bacterial pneumonia, allotype pneumonia, Suppurative lung disease, Syphilis, Otitis media, nasosinusitis, hypognathadenitis, Dysentery, enteritis, transmissible alimentary toxicosis, angiocholitis, cholecystitis, Peritonitis, bacteremia, community-acquired pneumonia, gynecological infections, urogenital tract infection, endocarditis, bacterial infection, ,meningitis, and granulocytopenia; analgesics; drugs for medical purposes for the treatment of cancers, the prevention of organ rejection in renal transplant patients, hypertension, hyperlipidemia, hypercholesterolemia, heart disease, prevention of chest pain, congestive heart failure, diabetes, respiratory tract infections, Urinary tract infections, Intra-abdominal infections, Skin and skin structure infections, Bacterial septicemia, Gynecological infections, Febrile neutropenic infections, Bone and joint infections, Polymicrobic infections, Urethritis, non-gonococcal urethritis, prostatitis, gonorrhea, cystitis, epididymitis, intrauterine infection, pyelonephritis, endonephritis, pyelocystitis, Superficial pyogenic infection, Deep suppurative disease, bronchitis, asthmatoid bronchitis, bronchiectasis, alveobronchiolitis, bacterial pneumonia, allotype pneumonia, Suppurative lung disease, Syphilis, Otitis media, nasosinusitis, hypognathadenitis, Dysentery, enteritis, transmissible alimentary toxicosis, angiocholitis, cholecystitis, Peritonitis and Septicemia, bacteremia, community-acquired pneumonia, septicemia, urogenital tract infection, endocarditis, bacterial infection, urinary tract infection, meningitis, granulocytopenia, Rheumatic Disorders, Collagen Diseases, Dermatologic Diseases, Allergic States, Ophthalmic Diseases, Respiratory Diseases, Hematologic Disorders, Neoplastic Diseases, Edematous States, gastric ulcer, duodenal ulcer, reflux esophagitis and Zollinger-Ellison syndrome, depression, obsessive-compulsive disorder, schizophrenia, epilepsy, seizures, spasms, Endocrine Disorders, adrenocortical insufficiency; capsules for medicines sold empty; sedatives; tranquillizers; biological preparations for medical purposes for the treatment of Pneumonia, urinary tract infection, Gynecological infections, Skin and skin structure infections, meningitis, septicemia; chemical preparations for pharmaceutical purposes for the treatment of cancers, prevention of organ rejection in renal transplant patients, hypertension, hyperlipidemia, hypercholesterolemia, heart disease, prevention of chest pain, congestive heart failure, diabetes, Rheumatic Disorders, Collagen Diseases, Dermatologic Diseases, Allergies, Ophthalmic Diseases, Respiratory Diseases, Hematologic Disorders, Neoplastic Diseases, Edematous States, gastric ulcer, duodenal ulcer, reflux esophagitis and Zollinger-Ellison syndrome, depression, obsessive-compulsive disorder, schizophrenia, epilepsy, seizures, spasms, Endocrine Disorders, adrenocortical insufficiency, respiratory tract infections, Community-acquired pneumonia, Nosocomial pneumonia, intra-abdominal infections , Skin and skin structure infections, endocarditis, pneumonia, urinary tract infection, Gynecological infections, meningitis, septicemia, Urethritis, non-gonococcal urethritis, prostatitis, gonorrhea, cystitis, epididymitis, intrauterine infection, pyelonephritis, endonephritis, pyelocystitis; chemical preparations for medical purposes for the treatment of cancers, the prevention of organ rejection in renal transplant patients, hypertension, hyperlipidemia, hypercholesterolemia, heart disease, prevention of chest pain, congestive heart failure, diabetes, Rheumatic Disorders, Collagen Diseases, Dermatologic Diseases, Allergies, Ophthalmic Diseases, Respiratory Diseases, Hematologic Disorders, Neoplastic Diseases, Edematous States, gastric ulcer, duodenal ulcer, reflux esophagitis and Zollinger-Ellison syndrome, depression, obsessive-compulsive disorder, schizophrenia, epilepsy, seizures, spasms, Endocrine Disorders, adrenocortical insufficiency, respiratory tract infections, Community-acquired pneumonia, Nosocomial pneumonia, Pseudomonas aeruginosa, Enterococcus faecalis, Staphylococcus aureus, Streptococcus anginosus, Streptococcus intermadius, Streptococcus constellatus, bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, clostridium perfringens, Peptostreptococcus micros, urogenital tract infection, endocarditis, pneumonia, urinary tract infection, Gynecological infections meningitis, Urethritis, non-gonococcal urethritis, prostatitis, gonorrhea, cystitis, epididymitis, intrauterine infection, pyelonephritis, endonephritis, pyelocystitis; antibiotics; Injectable pharmaceuticals for the treatment of Cancers, the prevention of organ rejection by renal transplant patients, hypertension, hyperlipidemia, hypercholesterolemia, heart disease, prevention of chest pain, chronic congestive heart failure, diabetes, Rheumatic Disorders, Collagen Diseases, Dermatologic Diseases, Allergic States, Ophthalmic Diseases, Respiratory Diseases, Hematologic Disorders, Neoplastic Diseases, Edematous States, gastric ulcer, duodenal ulcer, reflux esophagitis, Zollinger-Ellison syndrome, depression, obsessive-compulsive disorder, schizophrenia, epilepsy, seizures, spasms, Endocrine Disorders, adrenocortical insufficiency, respiratory tract infections, Urinary tract infections, Intra-abdominal infections, Skin and skin structure infections, septicemia, Gynecological infections, Febrile neutropenic infections, Bone and joint infections, Polymicrobic infections, Urethritis, non-gonococcal urethritis, prostatitis, gonorrhea, cystitis, epididymitis, intrauterine infection, pyelonephritis, endonephritis, pyelocystitis, Superficial pyogenic infection, Deep suppurative disease, bronchitis, asthmatoid bronchitis, bronchiectasis, alveobronchiolitis, bacterial pneumonia, allotype pneumonia, Suppurative lung disease, Syphilis, Otitis media, nasosinusitis, hypognathadenitis, Dysentery, enteritis, transmissible alimentary toxicosis, angiocholitis, cholecystitis, Peritonitis and Septicemia, community-acquired pneumonia, urogenital tract infection, endocarditis, bacterial infection, meningitis, and granulocytopenia; Bulk drugs, namely active pharmaceutical ingredients for a wide variety of pharmaceuticals; biochemical medicines for the treatment of Pneumonia, urinary tract infection, Gynecological infections, Skin and skin structure infections, meningitis, septicemia; blood products, namely, blood and blood plasma; tinctures, namely, pharmaceutical preparations deriving from crude drugs being immersed in alcohol; diagnostic preparations for medical purposes; chemical reagents for medical or veterinary purposes; radium for medical purposes; radioactive substances for use in nuclear medicine; isotopes for medical purposes; radioactive substances for medical purposes; oxygen baths preparations for medical use; gases for medical use; oxygen for medical purposes; chemical conductors for electrocardiograph electrodes; semen for artificial insemination; disinfectants for hygienic purposes; disinfectants; contact lens solution; contact lens cleaning preparations; cleaning solutions for use with contact lenses; bacteriological culture mediums; bouillons for bacteriological cultures; nutritive substances for microorganisms for medical purposes; cultures of microorganisms for medical and veterinary use; dietetic pasta, crackers and sugar for medical use; nutritional supplements; food for babies; infant milk powder; air purifying preparations; disinfectants for chemical toilets; medicines for veterinary purposes for the treatment of Pneumonia, urinary tract infection, Gynecological infections , Skin and skin structure infections, meningitis, septicemia; biological preparations for veterinary purposes for the treatment of Pneumonia, urinary tract infection, Gynecological infections, Skin and skin structure infections, meningitis, septicemia; chemical preparations for veterinary purposes for the treatment of Pneumonia, urinary tract infection, Gynecological infections , Skin and skin structure infections, meningitis, septicemia; dietary supplements for animals; pesticides; vermin destroying preparations; disinfectant wipes; wadding for medical purposes; dental abrasives; dental mastics | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Hisun Pfizer Pharmaceuticals Co., Ltd.
- Other trademarks owned by Hisun Pfizer Pharmaceuticals Co., Ltd.
- Other trademarks owned by Hisun Pfizer Pharmaceuticals Co., Ltd.
- Other trademarks owned by HANHUI PHARMACEUTICALS CO., LTD.
- Other trademarks in Class 005
- Similar marks named H
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 8, 2023 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Feb 28, 2022 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Sep 27, 2019 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 19, 2018 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Feb 28, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 20, 2017 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Jan 20, 2017 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Dec 21, 2016 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Dec 21, 2016 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| Dec 20, 2016 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 25, 2016 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 25, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 5, 2016 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 15, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 25, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 24, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 24, 2016 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Feb 24, 2016 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Feb 24, 2016 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 24, 2016 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 30, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 29, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 29, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 3, 2015 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 3, 2015 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 3, 2015 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 1, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| May 2, 2015 | MDSM | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| May 1, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 25, 2015 | NWAP | NEW APPLICATION ENTERED | — |